Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, 2-part, 2-period Fixed-sequence Study to Evaluate the Effect of Fruquintinib on the Pharmacokinetics of Dabigatran Etexilate (A P-GP Substrate) and Rosuvastatin (A BCRP Substrate) in Healthy Subjects
Conditions
Interventions
Fruquintinib
Dabigatran Etexilate
+1 more
Locations
1
United States
PPD Development
Austin, Texas, United States
Start Date
March 2, 2022
Primary Completion Date
April 22, 2022
Completion Date
April 22, 2022
Last Updated
October 6, 2022
NCT07446322
NCT07536113
NCT07416552
NCT07228832
NCT04657068
NCT06625775
Lead Sponsor
Hutchmed
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions